Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.




What is Atenolol?

What does Atenolol look like?

What are the available doses of Atenolol?

Sorry No records found.

What should I talk to my health care provider before I take Atenolol?

Sorry No records found

How should I use Atenolol?

What interacts with Atenolol?

Sorry No Records found

What are the warnings of Atenolol?

Cardiac Failure

In Patients Without a History of Cardiac Failure



Cessation of Therapy with Atenolol



Concomitant Use of Calcium Channel Blockers



Bronchospastic Diseases

PATIENTS WITH BRONCHOSPASTIC DISEASE SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS. Because of its relative beta selectivity, however, atenolol may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. Since betaselectivity is not absolute, the lowest possible dose of atenolol should be used with therapy initiated at 50 mg and a beta-stimulating agent (bronchodilator) should be made available. If dosage must be increased, dividing the dose should be considered in order to achieve lower peak blood levels.

Anesthesia and Major Surgery



Diabetes and Hypoglycemia




Untreated Pheochromocytoma

Pregnancy and Fetal Injury


PRECAUTIONS, Nursing Mothers

What are the precautions of Atenolol?


Impaired Renal Function

Drug Interactions



Carcinogenesis, Mutagenesis, Impairment of Fertility

in vivo

S typhimurium

Animal Toxicology

Usage in Pregnancy


WARNINGS - Pregnancy and Fetal Injury

Nursing Mothers


WARNINGS, Pregnancy and Fetal Injury

Pediatric Use

Geriatric Use

Hypertension and Angina Pectoris Due to Coronary Atherosclerosis

Acute Myocardial Infarction



What are the side effects of Atenolol?

Most adverse effects have been mild and transient.

The frequency estimates in the following table were derived from controlled studies in hypertensive patients in which adverse reactions were either volunteered by the patient (US studies) or elicited, e.g., by checklist (foreign studies). The reported frequency of elicited adverse effects was higher for both atenolol and placebo-treated patients than when these reactions were volunteered. Where frequency of adverse effects of atenolol and placebo is similar, causal relationship to atenolol is uncertain.

Volunteered( )  Total-Volunteeredand Elicited ( )  
Atenolol(n = 164)% Placebo(n = 206) % Atenolol(n = 399) % Placebo(n = 407) %
Bradycardia  3 0 3 0
Cold Extremities  0 0.5 12 5
Postural Hypotension  2 1 4 5
Leg Pain  0 0.5 3 1
Dizziness  4 1 13 6
Vertigo  2 0.5 2 0.2
Lightheadedness  1 0 3 0.7
Tiredness  0.6 0.5 26 13
Fatigue  3 1 6 5
Lethargy  1 0 3 0.7
Drowsiness  0.6 0 2 0.5
Depression  0.6 0.5 12 9
Dreaming  0 0 3 1
Diarrhea  2 0 3 2
Nausea  4 1 3 1
Wheeziness  0 0 3 3
Dyspnea  0.6 1 6 4

Acute Myocardial Infarction

In a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta-blocker, in atenolol-treated patients than in control patients. However, these usually responded to atropine and/or to withholding further dosages of atenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and other events occurring during these investigations is given in the following table.

In a study of 477 patients, the following adverse events were reported during either intravenous and/or oral atenolol administration:

In the subsequent International Study of Infarct Survival (ISIS-1) including over 16,000 patients of whom 8,037 were randomized to receive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons:

During postmarketing experience with atenolol, the following have been reported in temporal relationship to the use of the drug: elevated liver enzymes and/or bilirubin, hallucinations, headache, impotence, Peyronie's disease, postural hypotension which may be associated with syncope, psoriasiform rash or exacerbation of psoriasis, psychoses, purpura, reversible alopecia, thrombocytopenia, visual disturbances, sick sinus syndrome, and dry mouth. Atenolol, like other beta-blockers, has been associated with the development of antinuclear antibodies (ANA), lupus syndrome, and Raynaud’s phenomenon.

Conventional TherapyPlus Atenolol(n=244) ConventionalTherapy Alone(n=233)
Bradycardia 43 (18%) 24 (10%)
Hypotension 60 (25%) 34 (15%)
Bronchospasm 3 (1.2%) 2 (0.9%)
Heart Failure 46 (19%) 56 (24%)
Heart Block 11 (4.5%) 10 (4.3%)
BBB + MajorAxis Deviation 16 (6.6%) 28 (12%)
Supraventricular Tachycardia 28 (11.5%) 45 (19%)
Atrial Fibrillation 12 (5%) 29 (11%)
Atrial Flutter 4 (1.6%) 7 (3%)
Ventricular Tachycardia 39 (16%) 52 (22%)
Cardiac Reinfarction 0 (0%) 6 (2.6%)
Total Cardiac Arrests 4 (1.6%) 16 (6.9%)
Nonfatal Cardiac Arrests 4 (1.6%) 12 (5.1%)
Deaths 7 (2.9%) 16 (6.9%)
Cardiogenic Shock 1 (0.4%) 4 (1.7%)
Development of VentricularSeptal Defect 0 (0%) 2 (0.9%)
Development of MitralRegurgitation 0 (0%) 2 (0.9%)
Renal Failure 1 (0.4%) 0 (0%)
Pulmonary Emboli 3 (1.2%) 0 (0%)
Full dosage was 10 mg and some patients received less than 10 mg but more than 5 mg.Oral PartialDose
Hypotension / Bradycardia  105 (1.3%) 1168 (14.5%)
Cardiogenic Shock  4 (.04%) 35 (.44%)
Reinfarction  0 (0%) 5 (.06%)
Cardiac Arrest  5 (.06%) 28 (.34%)
Heart Block (> first degree)  5 (.06%) 143 (1.7%)
Cardiac Failure  1 (.01%) 233 (2.9%)
Arrhythmias  3 (.04%) 22 (.27%)
Bronchospasm  1 (.01%) 50 (.62%)

What should I look out for while using Atenolol?

What might happen if I take too much Atenolol?


How should I store and handle Atenolol?

Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F) [see USP Controlled Room Temperature].They are supplied by as follows:This Product was Repackaged By:State of Florida DOH Central PharmacyThey are supplied by as follows:This Product was Repackaged By:State of Florida DOH Central PharmacyThey are supplied by as follows:This Product was Repackaged By:State of Florida DOH Central Pharmacy


Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Non-Clinical Toxicology


This information is obtained from the National Institute of Health's Standard Packaging Label drug database.

While we update our database periodically, we cannot guarantee it is always updated to the latest version.



Rate this treatment and share your opinion

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment


Click the stars to rate this treatment

This medication has worked for me.

This medication has been easy for me to use.

Overall, I have been satisfied with my experience.

Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:


Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72






A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).